Search the GHTC website

Global health R&D delivers for New York

US government investment in global health R&D has delivered

$916.0 million
to New York research institutions
9,600+ new jobs
for New York
New York's top USG-funded global health R&D institutions

New York's top USG-funded global health R&D institutions

International AIDS Vaccine Initiative
$302.4 million
Cornell University (including Weill Cornell Medical College)
$96.5 million
Yeshiva University (including Albert Einstein College of Medicine)
$95.3 million
Population Council
$78 million
New York University School of Medicine
$72 million
TB Alliance
$36.2 million
Columbia University (including Health Sciences)
$30 million
University of Rochester
$25.9 million
Icahn School of Medicine at Mount Sinai (formerly the Mount Sinai School of Medicine)
$24.7 million
Wadsworth Center, New York State Department of Health
$19.5 million
Aaron Diamond AIDS Research Center
$16.3 million
State University of New York at Buffalo
$15.5 million
Trudeau Institute, Inc.
$11.3 million
Sloan-Kettering Institute for Cancer Research
$11.3 million
State University of New York at Stony Brook
$9 million
Mayo Clinic (including Mayo Medical School)
$6.6 million
New York Blood Center
$4.6 million
Brooklyn College
$4.3 million
Upstate Medical University
$3.8 million
Albany Medical College
$3.6 million
Renssalaer Polytechnic Institute
$3.5 million
Brookhaven Science Association
$3.4 million
St. Luke's-Roosevelt Institute for Health Sciences
$1.8 million
Global HIV Vaccine Enterprise
$1.4 million
State University of New York at Albany
$1.4 million
State University of New York Binghamton
$1.2 million
New York Medical College
$1 million
amfAR, The Foundation for AIDS Research
$725 thousand
Hunter College
$483 thousand
State University of New York Geneseo
$416 thousand
St. John's University
$303 thousand
The City University of New York
$201 thousand
Queens College, City University of New York
SUNY Downstate Medical Center
$147 thousand
Syracuse University
$89 thousand
Bronx-Lebanon Hospital Center
$29 thousand
Health Research, Inc.
$25 thousand
New York Academy of Sciences
$6 thousand
New York industry in global health R&D

New York industry in global health R&D

BASF Corporation
Location(s): Tarrytown
Bristol-Myers Squibb
Location(s): New York City, Syracuse
Buffalo BioLabs
Location(s): Buffalo
Charles River Laboratories
Location(s): Kingston
Chembio Diagnostic Systems
Location(s): Medford
Location(s): Central Islip
Disease Diagnostic Group
Location(s): Buffalo
Eli Lilly and Company
Location(s): New York City
Location(s): New York City
Location(s): Brooklyn
Medical Avatar
Location(s): New York City
Location(s): New York City, Melville, Suffern
Location(s): New York City, Pearl River
Profectus BioSciences
Location(s): Tarrytown
Location(s): Rensselaer
Location(s): Rensselaer, Sleepy Hollow, Tarrytown
Location(s): New York City
Location(s): Tarrytown
United Biomedical
Location(s): Hauppauge
Ultimate Medical Products
Location(s): Rockville Centre
ZeptoMetrix Corporation
Location(s): Buffalo

New York's top areas of global health R&D by USG funding

Diarrheal diseases
Ebola/viral hemorrhagic fevers
Neglected tropical diseases
Bacterial pneumonia & meningitis
Cryptococcal meningitis
Salmonella infections
Rheumatic fever
Global health R&D at work in New York

The International AIDS Vaccine Initiative (IAVI) is working to develop HIV vaccines and other prevention tools. Research by IAVI and partners has yielded insights into how the immune system attempts to control the virus, how HIV evades immune defenses, how disease progression varies by virus strain, and how some people living with HIV naturally produce antibodies against a broad array of HIV types. IAVI is supporting development and testing of 11 vaccine candidates.

  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: International AIDS Vaccine Initiative